Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IBU-TAB vs DAYPRO
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby alleviating pain and inflammation.
Rheumatoid arthritis,Osteoarthritis,Mild to moderate pain,Primary dysmenorrhea,Fever reduction,Gouty arthritis (off-label),Patent ductus arteriosus closure in neonates (off-label)
Osteoarthritis,Rheumatoid arthritis
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
600 mg orally once daily; max 1200 mg/day
2-4 hours (terminal elimination half-life); in overdose or hepatic impairment, may be prolonged to >4 hours. Clinically, the short half-life supports dosing every 6-8 hours for acute pain.
Approximately 40-70 hours (mean ~50 h), allowing once-daily dosing; steady-state reached in 4-6 days.
Primarily hepatic via CYP2C9; also undergoes glucuronidation. Metabolites include hydroxy- and carboxy-ibuprofen, which are inactive.
Primarily hepatic via CYP2C9; undergoes glucuronidation.
Renal excretion of conjugated metabolites (approximately 90% of an administered dose) with less than 1% excreted unchanged. Biliary/fecal elimination accounts for less than 5%.
Renal (approx. 70-80% as unchanged drug and glucuronide conjugate; biliary/fecal excretion accounts for the remainder).
Approximately 99% bound to albumin.
>99% bound primarily to albumin.
0.1-0.3 L/kg. The low Vd indicates limited tissue distribution, primarily confined to plasma and extracellular fluid.
0.15-0.2 L/kg; indicates limited extravascular distribution mainly in plasma and extracellular fluid.
Oral: 80-100% (well absorbed). Topical: approximately 5-10% systemically absorbed (varies with formulation and application site).
Oral: approximately 80-90%.
Cr Cl 30-60 m L/min: reduce dose by 50% and avoid in Cr Cl <30 m L/min.
Cr Cl 30-59 m L/min: 600 mg once daily; Cr Cl <30 m L/min: 400 mg once daily; hemodialysis: 400 mg once daily after dialysis
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Child-Pugh Class A: no adjustment; Class B: 400 mg once daily; Class C: avoid use
5-10 mg/kg/dose orally every 6-8 hours; maximum 40 mg/kg/day.
Not approved for pediatric use
Initiate at lowest effective dose (e.g., 200 mg every 8-12 hours); monitor renal function and avoid long-term use.
Initiate at 400 mg once daily; max 600 mg once daily; monitor renal function
NSAIDs increase the risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk increases with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. NSAIDs are contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. DAYPRO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.
Risk of serious GI adverse events including bleeding, ulceration, and perforation; NSAIDs should be used with caution in patients with history of peptic ulcer disease or GI bleeding. May cause renal toxicity, especially in patients with pre-existing renal impairment. Use with caution in patients with asthma, congestive heart failure, or hypertension.
Cardiovascular risk, gastrointestinal bleeding and ulceration, renal toxicity, hypertension, anaphylactoid reactions, serious skin reactions, hematologic toxicity (anemia), hepatic effects, asthma exacerbation, fluid retention, and use in pregnancy (avoid in late pregnancy).
History of hypersensitivity to ibuprofen or any other NSAID; active peptic ulcer disease or GI bleeding; severe renal impairment; history of serious cardiovascular event; perioperative pain in CABG surgery; third trimester of pregnancy.
Aspirin allergy, history of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, perioperative pain in the setting of CABG surgery, advanced renal disease, and pregnancy (third trimester).
Alcohol may increase risk of GI bleeding. Food delays absorption but does not significantly affect total exposure; take with food to improve tolerability.
No significant food interactions. However, taking with food or antacids can reduce GI irritation. Avoid alcohol to minimize risk of gastric mucosal injury.
First trimester: Association with increased risk of miscarriage and congenital cardiac defects (odds ratio 1.86). Second/third trimester: Premature closure of ductus arteriosus, oligohydramnios, fetal renal impairment; avoid after 30 weeks gestation. Use not recommended during pregnancy.
Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with teratogenic potential. First trimester: Avoid; associated with increased risk of miscarriage and cardiac defects. Second trimester: Use only if clearly needed; possible oligohydramnios and fetal renal impairment. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal pulmonary hypertension.
Excreted in breast milk in low concentrations (M/P ratio <0.02). American Academy of Pediatrics considers compatible with breastfeeding. Monitor infant for gastrointestinal distress or rash. Use lowest effective dose for shortest duration.
Oxaprozin is excreted into breast milk in low concentrations (M/P ratio approximately 0.1-0.3). Due to potential adverse effects on infant renal function and platelet function, caution is advised. Avoid long-term use; short-term use with infant monitoring recommended.
Increased clearance and volume of distribution in pregnancy (especially third trimester) may require dose escalation to maintain efficacy. However, due to fetal risks, avoid use; if necessary, use minimal effective dose for shortest duration.
No specific dose adjustments established; however, pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may require dose titration based on clinical response. Use lowest effective dose for shortest duration. Avoid in third trimester.
IBU-TAB (ibuprofen) is a non-selective COX inhibitor; use lowest effective dose for shortest duration to minimize GI and renal risks. Avoid in patients with NSAID-sensitive asthma, severe renal impairment (e GFR <30 m L/min), or perioperative pain in CABG surgery. Concomitant aspirin antagonizes irreversible antiplatelet effect; separate by 2 hours if immediate-release. Monitor for fluid retention and hypertension in cardiac patients.
Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with a long half-life (~50-60 hours) allowing once-daily dosing. Use with caution in elderly or renal impairment due to reduced clearance. Monitor renal function, hepatic enzymes, and signs of GI bleeding. Avoid use with other NSAIDs or aspirin. May increase lithium, methotrexate, and warfarin levels.
Take with food or milk to reduce stomach upset.,Do not exceed 1200 mg/day without physician approval; higher doses increase risk of bleeding and kidney damage.,Avoid alcohol while taking this medication to reduce risk of stomach bleeding.,Discontinue and seek medical help if you experience signs of allergic reaction (rash, swelling, difficulty breathing) or black/tarry stools.,Inform your doctor about all medications you take, especially blood thinners, aspirin, other NSAIDs, and medications for blood pressure or kidney disease.
Take with food or milk to reduce stomach upset.,Swallow tablets whole; do not crush or chew.,Avoid alcohol while taking this medication.,Report signs of bleeding (black/tarry stools, unusual bruising), weight gain, or edema.,Do not take with other NSAIDs or over-the-counter pain relievers without consulting your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IBU-TAB vs DAYPRO, answered by our medical review team.
IBU-TAB is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Non-selective inhibition of cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, inflammation, and fever.. DAYPRO is a Nonsteroidal Anti-Inflammatory Drug (NSAID) that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and thereby alleviating pain and inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IBU-TAB and DAYPRO depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IBU-TAB is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.. The standard adult dose of DAYPRO is: 600 mg orally once daily; max 1200 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IBU-TAB and DAYPRO in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IBU-TAB is classified as Category C. First trimester: Association with increased risk of miscarriage and congenital cardiac defects (odds ratio 1.86). Second/third trimester: Premature closure of ductus arteriosus, ol. DAYPRO is classified as Category C. Daypro (oxaprozin) is a nonsteroidal anti-inflammatory drug (NSAID) with teratogenic potential. First trimester: Avoid; associated with increased risk of miscarriage and cardiac de. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.